- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Obesity, C-Reactive Protein, and Calprotectin in Adalimumab-Treated Rheumatoid Arthritis Patients: Association with Clinical Response: A cross-sectional comparative study | ||
| Al-Kunooze Scientific Journal | ||
| Volume 12, Issue 3, July 2026, Pages 214-225 PDF (943.67 K) | ||
| Document Type: Original Article | ||
| DOI: 10.36582/ksj.2026.171634.1056 | ||
| Authors | ||
| Ghasaq Kareem Abed* 1; Asma Abdul Jaleel Swadi1; Zahraa Hussam ALzubaidi2 | ||
| 1College of Medicine, University of Al-Qadisiyah, Al-Diwaniyah/ Iraq | ||
| 2Al-Hamzah General Hospital, Al-Qadisiyah Health Directorate, Al-Diwaniyah, Iraq | ||
| Abstract | ||
| Rheumatoid arthritis (RA) is a long-lasting inflammatory illness considered via synovial inflammation as well as joint destruction. Tumor necrosis factor-alpha and interleukin-6 are key mediators. Adalimumab is operative; a percentage of patients show inadequate response. C-reactive protein and erythrocyte sedimentation rate are generally run down inflammatory markers, but limited ability to predict treatment response. Calprotectin has been projected as a biomarker of illness activity. To assess serum CRP and calprotectin ranks in RA patients cured with adalimumab and to evaluate their connotation with BMI and medical response. A cross-sectional comparative study included 130 participants: 75 RA patients receiving adalimumab and 55 controls. Patients included 25 males and 50 females; mean age 47.57 ±10.68 (responders n = 35) and 46.40 ±8.76 (non-responders n = 40), categorized rendering to European Alliance of Associations for Rheumatology principles, using Disease Activity Score28 with Erythrocyte sedimentation rate. CRP and calprotectin were restrained using Enzyme-Linked Immunosorbent Assay. RA patients showed higher CRP and calprotectin ranks paralleled to controls (p < 0.001). Calprotectin did not diverge among responders and non-responders, while CRP was higher in non-responders (p < 0.001). BMI was positively associated with calprotectin (r = 0.746) and CRP (r = 0.655) (p < 0.001). CRP and calprotectin are elevated in RA patients treated with adalimumab; Only CRP is associated with treatment response. Calprotectin reflects inflammatory burden, while obesity is related with augmented inflammatory indicators and may negatively influence outcomes. | ||
| Keywords | ||
| Rheumatoid arthritis; Obesity; Calprotectin; CRP; Adalimumab | ||
|
Statistics Article View: 207 PDF Download: 98 |
||